CASI Pharmaceuticals, Inc. (CASI)
NASDAQ: CASI · Real-Time Price · USD
0.960
-0.018 (-1.86%)
At close: Dec 5, 2025, 4:00 PM EST
1.020
+0.060 (6.24%)
After-hours: Dec 5, 2025, 7:46 PM EST
CASI Pharmaceuticals Revenue
CASI Pharmaceuticals had revenue of $3.08M in the quarter ending September 30, 2025, a decrease of -60.54%. This brings the company's revenue in the last twelve months to $26.85M, up 21.72% year-over-year. In the year 2024, CASI Pharmaceuticals had annual revenue of $28.54M, down -15.77%.
Revenue (ttm)
$26.85M
Revenue Growth
+21.72%
P/S Ratio
0.59
Revenue / Employee
$115,219
Employees
233
Market Cap
19.73M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 28.54M | -5.34M | -15.77% |
| Dec 31, 2023 | 33.88M | -9.23M | -21.41% |
| Dec 31, 2022 | 43.11M | 12.94M | 42.89% |
| Dec 31, 2021 | 30.17M | 15.03M | 99.25% |
| Dec 31, 2020 | 15.14M | 11.01M | 266.52% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
CASI News
- 17 days ago - CASI Pharmaceuticals Announces Changes in Board Governance - Accesswire
- 21 days ago - CASI Pharmaceuticals Announces Third Quarter 2025 Business and Financial Results - Accesswire
- 25 days ago - CASI Pharmaceuticals Receives and Appeals Delisting Determination from NASDAQ - Accesswire
- 4 weeks ago - CASI Pharmaceuticals to Participate at Guggenheim Healthcare Innovation Conference - Accesswire
- 4 weeks ago - CASI Pharmaceuticals Announces Upcoming Presentation of Clinical Results for CID-103 at the 67th American Society of Hematology (ASH) Annual Meeting - Accesswire
- 2 months ago - CASI Pharmaceuticals Appoints James Huang to Board of Directors - Accesswire
- 3 months ago - CASI Pharmaceuticals Announces Safety Monitoring Committee Recommendation to Escalate CID-103 Dose to Next Cohort in Phase 1 Immune Thrombocytopenia (ITP) Study - Accesswire
- 3 months ago - CASI Pharmaceuticals to Present at H.C. Wainwright 27th Annual Global Investment Conference - Accesswire